Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Circulating PIWI-Interacting RNAs piR-5937 and piR-28876 Are Promising Diagnostic Biomarkers of Colon Cancer

P. Vychytilova-Faltejskova, K. Stitkovcova, L. Radova, M. Sachlova, Z. Kosarova, K. Slaba, Z. Kala, M. Svoboda, I. Kiss, R. Vyzula, WC. Cho, O. Slaby,

. 2018 ; 27 (9) : 1019-1028. [pub] 20180705

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035144

Grantová podpora
NV16-31765A MZ0 CEP - Centrální evidence projektů

Background: The early detection of colon cancer is one of the main prerequisites for successful treatment and mortality reduction. Circulating PIWI-interacting RNAs (piRNA) were recently identified as novel promising biomarkers. The purpose of the study was to assess the profiles of piRNAs in blood serum of colon cancer patients with the aim to identify those with high diagnostic potential.Methods: Blood serum samples from 403 colon cancer patients and 276 healthy donors were included in this 3-phase biomarker study. Large-scale piRNA expression profiling was performed using Illumina small RNA sequencing. The diagnostic potential of selected piRNAs was further validated on independent training and validation sets of samples using RT-qPCR.Results: In total, 31 piRNAs were found to be significantly deregulated in serum of cancer patients compared with healthy donors. Based on the levels of piR-5937 and piR-28876, it was possible to differentiate between cancer patients and healthy donors with high sensitivity and specificity. Moreover, both piRNAs exhibited satisfactory diagnostic performance also in patients with stage I disease and enabled detection of colon cancer with higher sensitivity than currently used biomarkers CEA and CA19-9. Finally, the expression of analyzed piRNAs in blood restored significantly 1 month after the surgical resection.Conclusions: Based on our findings, piRNAs are abundant in human blood serum. Furthermore, their levels in colon cancer have been observed to be significantly deregulated. However, their involvement in carcinogenesis must be further established.Impact: piRNAs could serve as promising noninvasive biomarkers for early detection of colon cancer. Cancer Epidemiol Biomarkers Prev; 27(9); 1019-28. ©2018 AACR.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035144
003      
CZ-PrNML
005      
20191014090014.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1055-9965.EPI-18-0318 $2 doi
035    __
$a (PubMed)29976566
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vychytilova-Faltejskova, Petra $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
245    10
$a Circulating PIWI-Interacting RNAs piR-5937 and piR-28876 Are Promising Diagnostic Biomarkers of Colon Cancer / $c P. Vychytilova-Faltejskova, K. Stitkovcova, L. Radova, M. Sachlova, Z. Kosarova, K. Slaba, Z. Kala, M. Svoboda, I. Kiss, R. Vyzula, WC. Cho, O. Slaby,
520    9_
$a Background: The early detection of colon cancer is one of the main prerequisites for successful treatment and mortality reduction. Circulating PIWI-interacting RNAs (piRNA) were recently identified as novel promising biomarkers. The purpose of the study was to assess the profiles of piRNAs in blood serum of colon cancer patients with the aim to identify those with high diagnostic potential.Methods: Blood serum samples from 403 colon cancer patients and 276 healthy donors were included in this 3-phase biomarker study. Large-scale piRNA expression profiling was performed using Illumina small RNA sequencing. The diagnostic potential of selected piRNAs was further validated on independent training and validation sets of samples using RT-qPCR.Results: In total, 31 piRNAs were found to be significantly deregulated in serum of cancer patients compared with healthy donors. Based on the levels of piR-5937 and piR-28876, it was possible to differentiate between cancer patients and healthy donors with high sensitivity and specificity. Moreover, both piRNAs exhibited satisfactory diagnostic performance also in patients with stage I disease and enabled detection of colon cancer with higher sensitivity than currently used biomarkers CEA and CA19-9. Finally, the expression of analyzed piRNAs in blood restored significantly 1 month after the surgical resection.Conclusions: Based on our findings, piRNAs are abundant in human blood serum. Furthermore, their levels in colon cancer have been observed to be significantly deregulated. However, their involvement in carcinogenesis must be further established.Impact: piRNAs could serve as promising noninvasive biomarkers for early detection of colon cancer. Cancer Epidemiol Biomarkers Prev; 27(9); 1019-28. ©2018 AACR.
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a nádory tračníku $x diagnóza $x genetika $7 D003110
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a malá interferující RNA $x genetika $7 D034741
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stitkovcova, Karolina $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Radova, Lenka $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Sachlova, Milana $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kosarova, Zdenka $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Slaba, Katerina $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Kala, Zdenek $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Surgery, Institutions Shared with the Faculty Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Svoboda, Marek $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Vyzula, Rostislav $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Cho, William C $u Cancer Research Unit, Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, PR China.
700    1_
$a Slaby, Ondrej $u Centre for Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. ondrej.slaby@ceitec.muni.cz. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00006442 $t Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology $x 1538-7755 $g Roč. 27, č. 9 (2018), s. 1019-1028
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29976566 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014090438 $b ABA008
999    __
$a ok $b bmc $g 1451804 $s 1073694
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 27 $c 9 $d 1019-1028 $e 20180705 $i 1538-7755 $m Cancer epidemiology, biomarkers & prevention $n Cancer Epidemiol Biomarkers Prev $x MED00006442
GRA    __
$a NV16-31765A $p MZ0
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace